X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-06-02 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $1.97 | -87,216 | 6,297,581 | -1% | -$172,191 | ||||||
| M | 2026-06-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $1.94 | -9,184 | 95,461 | -9% | -$17,813 | |||||
2026-06-02 | ALEC | Alector, Inc. | Berkley Neil Lindsay | CFO, Chief Business Officer | S - Sale | $1.97 | -19,360 | 379,900 | -5% | -$38,221 | ||||||
2026-06-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.20 | -6,643 | 372,867 | -2% | -$174,048 | ||||||
| D | 2026-06-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Pres, R, D, CMO | S - Sale+OE | $25.66 | -14,853 | 0 | -100% | -$381,112 | |||||
2026-06-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale | $49.52 | -2,250 | 158,494 | -1% | -$111,416 | ||||||
| D | 2026-06-01 | NBIX | Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $160.25 | -11,000 | 25,846 | -30% | -$1,762,710 | |||||
2026-06-01 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $131.46 | -15,000 | 617,567 | -2% | -$1,971,847 | ||||||
| D | 2026-05-29 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $156.71 | -2,261 | 16,225 | -12% | -$354,321 | |||||
2026-06-01 | VIR | Vir Biotechnology, Inc. | Napolitano Janet | Dir | S - Sale | $9.45 | -3,200 | 21,216 | -13% | -$30,240 | ||||||
2026-06-01 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | SVP, Chief Accounting Officer | S - Sale | $9.45 | -379 | 61,902 | -1% | -$3,582 | ||||||
2026-06-01 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $66.21 | -1,625 | 43,669 | -4% | -$107,591 | ||||||
2026-06-01 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $10.02 | -1,922 | 1,057,231 | 0% | -$19,258 | ||||||
| D | 2026-05-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $26.34 | -7,500 | 24,808 | -23% | -$197,554 | |||||
2026-05-29 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $69.75 | -14,205 | 120,094 | -11% | -$990,799 | ||||||
2026-05-29 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $70.00 | -4,000 | 112,675 | -3% | -$280,000 | ||||||
| D | 2026-06-01 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale+OE | $9.62 | -9,747 | 130,079 | -7% | -$93,766 | |||||
2026-06-01 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale | $19.44 | -5,466 | 594,538 | -1% | -$106,253 | ||||||
| D | 2026-05-28 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Ghiath M. | Dir, 10% | P - Purchase | $0.59 | +8,539,709 | 22,092,068 | +63% | +$5,000,000 | |||||
| D | 2026-05-29 | CRSP | Crispr Therapeutics AG | Patel Naimish | Chief Medical Officer | S - Sale+OE | $55.62 | -3,786 | 19,357 | -16% | -$210,577 | |||||
| D | 2026-05-28 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $67.91 | -16,470 | 846,872 | -2% | -$1,118,555 | |||||
2026-05-28 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Dir | S - Sale | $68.00 | -2,500 | 22,222 | -10% | -$170,000 | ||||||
| D | 2026-05-29 | GLUE | Monte Rosa Therapeutics, Inc. | Townson Sharon | Chief Scientific Officer | S - Sale+OE | $19.87 | -6,000 | 67,845 | -8% | -$119,220 | |||||
| M | 2026-05-27 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.90 | +73,738 | 2,694,107 | +3% | +$434,714 | |||||
| D | 2026-05-27 | NBIX | Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | S - Sale+OE | $155.53 | -11,000 | 25,846 | -30% | -$1,710,865 | |||||
| D | 2026-05-28 | IMVT | Immunovant, Inc. | Fromkin Andrew J. | Dir | S - Sale+OE | $33.51 | -221,951 | 74,382 | -75% | -$7,438,111 | |||||
| D | 2026-05-27 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $20.00 | -2,175 | 62,371 | -3% | -$43,500 | |||||
2026-05-26 | EXEL | Exelixis, Inc. | Aftab Dana | EVP, Research, Development | S - Sale | $50.35 | -43,451 | 600,576 | -7% | -$2,187,758 | ||||||
2026-05-26 | NBIX | Neurocrine Biosciences Inc | Boyer David W. | Chief Corp. Affairs Officer | S - Sale | $156.64 | -3,888 | 7,799 | -33% | -$609,023 | ||||||
2026-05-11 | ARTV | Artiva Biotherapeutics, Inc. | Gc Corp. | 10% | P - Purchase | $11.52 | +1,432,291 | 5,999,703 | +31% | +$16,499,992 | ||||||
2026-05-27 | ATYR | Atyr Pharma Inc | Schimmel Paul | Dir | P - Purchase | $0.50 | +100,000 | 2,201,056 | +5% | +$49,630 | ||||||
| D | 2026-05-26 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | See Remarks | S - Sale+OE | $153.99 | -3,121 | 54,400 | -5% | -$480,611 | |||||
2026-05-27 | ADMA | Adma Biologics, Inc. | Grossman Jerrold B | Dir | P - Purchase | $7.91 | +6,400 | 612,991 | +1% | +$50,624 | ||||||
2026-05-26 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Dir | S - Sale | $61.04 | -500 | 24,722 | -2% | -$30,520 | ||||||
| DM | 2026-05-26 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $65.19 | -49,299 | 846,872 | -6% | -$3,213,653 | |||||
2026-05-26 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $62.48 | -800 | 48,186 | -2% | -$49,987 | ||||||
| M | 2026-05-26 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $79.92 | -17,184 | 44,018 | -28% | -$1,373,290 | |||||
2026-05-26 | KRYS | Krystal Biotech, Inc. | Thomas John Charles | EVP, GC | S - Sale | $302.03 | -642 | 0 | -100% | -$193,903 | ||||||
| M | 2026-05-22 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.01 | -32,564 | 379,510 | -8% | -$847,048 | |||||
| D | 2026-05-22 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | Dir | S - Sale+OE | $3.08 | -40,000 | 883,735 | -4% | -$123,200 | |||||
2026-05-27 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Faisal Ghiath | Dir | P - Purchase | $0.41 | +122,174 | 125,574 | >999% | +$50,006 | ||||||
2026-05-26 | OTLK | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Dir | P - Purchase | $0.44 | +34,000 | 37,167 | >999% | +$14,960 | ||||||
2026-05-26 | OTLK | Outlook Therapeutics, Inc. | Thurman Randy H | Dir | P - Purchase | $0.43 | +5,000 | 5,593 | +843% | +$2,145 | ||||||
2026-05-26 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.44 | +400,000 | 423,655 | >999% | +$176,520 | ||||||
| D | 2026-05-22 | PTHS | Pelthos Therapeutics Inc. | Francis Knuettel II | CFO, Treas, Secty | S - Sale+OE | $26.84 | -1,500 | 40,841 | -4% | -$40,265 | |||||
2026-05-22 | VXRT | Vaxart, Inc. | Watson W. Mark | Dir | P - Purchase | $0.65 | +10,000 | 134,125 | +8% | +$6,530 | ||||||
| D | 2026-05-22 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $8.33 | -307 | 50,704 | -1% | -$2,559 | |||||
2026-05-21 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $53.26 | -1,399 | 121,589 | -1% | -$74,507 | ||||||
2026-05-21 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $53.26 | -4,160 | 274,804 | -1% | -$221,549 | ||||||
2026-05-21 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $53.26 | -1,642 | 134,299 | -1% | -$87,448 | ||||||
2026-05-21 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $53.26 | -688 | 48,986 | -1% | -$36,641 | ||||||
| D | 2026-05-21 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $53.26 | -6,888 | 846,872 | -1% | -$366,834 | |||||
2026-05-21 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $53.26 | -2,019 | 116,675 | -2% | -$107,526 | ||||||
| D | 2026-05-22 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $19.00 | -2,176 | 62,371 | -3% | -$41,344 | |||||
2026-05-20 | KLRS | Kalaris Therapeutics, Inc. | Akkaraju Srinivas | Dir, 10% | P - Purchase | $4.83 | +244,300 | 12,915,520 | +2% | +$1,179,969 | ||||||
| D | 2026-05-21 | MRNA | Moderna, Inc. | Afeyan Noubar | Dir | S - Sale+OE | $46.84 | -9,263 | 6,856,164 | 0% | -$433,879 | |||||
2026-05-20 | EXEL | Exelixis, Inc. | Haley Patrick J. | EVP, Commercial | S - Sale | $49.81 | -32,110 | 357,638 | -8% | -$1,599,399 | ||||||
| M | 2026-05-20 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.77 | +24,376 | 2,620,369 | +1% | +$140,545 | |||||
| D | 2026-05-21 | GLUE | Monte Rosa Therapeutics, Inc. | Manning Anthony M. | Dir | S - Sale+OE | $18.01 | -10,000 | 0 | -100% | -$180,100 | |||||
2026-05-20 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $32.45 | -3,115 | 242,107 | -1% | -$101,072 | ||||||
| M | 2026-05-19 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.92 | +1,700 | 293,266 | +1% | +$1,570 | |||||
| D | 2026-05-19 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | Dir | S - Sale+OE | $154.33 | -245,088 | 511,293 | -32% | -$37,824,872 | |||||
| M | 2026-05-19 | COAG | Hemab Therapeutics Holdings, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $24.96 | +4,798 | 7,740,958 | 0% | +$119,776 | |||||
2026-05-20 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $1.88 | -25,590 | 628,155 | -4% | -$48,084 | ||||||
2026-05-20 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $1.88 | -28,946 | 635,762 | -4% | -$54,482 | ||||||
| D | 2026-05-20 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $32.00 | -6,000 | 136,731 | -4% | -$192,000 | |||||
2026-05-18 | ADPT | Adaptive Biotechnologies Corp | Piskel Kyle | CFO | S - Sale | $13.04 | -3,115 | 256,725 | -1% | -$40,620 | ||||||
2026-05-18 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $9.13 | -5,241 | 137,837 | -4% | -$47,845 | ||||||
2026-05-18 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $9.13 | -2,414 | 49,636 | -5% | -$22,036 | ||||||
2026-05-19 | HUMA | Humacyte, Inc. | Sebelius Kathleen | Dir | P - Purchase | $0.88 | +56,818 | 148,025 | +62% | +$50,000 | ||||||
2026-05-18 | HUMA | Humacyte, Inc. | Constantino Michael T. | Dir | P - Purchase | $0.89 | +11,000 | 43,950 | +33% | +$9,840 | ||||||
2026-05-18 | HUMA | Humacyte, Inc. | Sander Dale A. | CFO, Chief Corp. Dev. Off | S - Sale | $0.90 | -45,887 | 307,813 | -13% | -$41,147 | ||||||
2026-05-18 | HUMA | Humacyte, Inc. | Parikh Shamik J | Chief Medical Officer | S - Sale | $0.90 | -45,887 | 272,713 | -14% | -$41,147 | ||||||
2026-05-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | COO | S - Sale | $5.07 | -1,302 | 130,088 | -1% | -$6,606 | ||||||
2026-05-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $5.06 | -3,342 | 336,764 | -1% | -$16,927 | ||||||
2026-05-18 | REPL | Replimune Group, Inc. | Xynos Konstantinos | Chief Medical Officer | S - Sale | $5.08 | -14,023 | 235,662 | -6% | -$71,237 | ||||||
2026-05-18 | REPL | Replimune Group, Inc. | Schwendenman Andrew | Chief Accounting Officer | S - Sale | $5.08 | -7,894 | 107,057 | -7% | -$40,102 | ||||||
2026-05-18 | REPL | Replimune Group, Inc. | Sarchi Christopher | Chief Commercial Officer | S - Sale | $5.08 | -8,626 | 192,962 | -4% | -$43,820 | ||||||
2026-05-18 | REPL | Replimune Group, Inc. | Astley-Sparke Philip | Dir | S - Sale | $5.08 | -17,657 | 1,412,414 | -1% | -$89,698 | ||||||
2026-05-18 | REPL | Replimune Group, Inc. | Patel Sushil | CEO | S - Sale | $5.08 | -37,324 | 747,492 | -5% | -$189,606 | ||||||
2026-05-18 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $5.08 | -7,812 | 236,556 | -3% | -$39,685 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Raymon Heather | SVP, Research, Development | S - Sale | $9.01 | -3,095 | 148,228 | -2% | -$27,879 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Horan Christopher | Chief Tech Operations Officer | S - Sale | $9.01 | -7,002 | 293,450 | -2% | -$63,073 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Bush Jennifer | COO, CLO, Compliance Officer | S - Sale | $9.01 | -8,790 | 337,920 | -3% | -$79,179 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Chief Medical Officer | S - Sale | $9.01 | -7,037 | 144,963 | -5% | -$63,386 | ||||||
2026-05-19 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | CEO | S - Sale | $9.01 | -27,116 | 1,535,082 | -2% | -$244,253 | ||||||
2026-05-19 | MGTX | Meiragtx Holdings Plc | Forbes Alexandria | Pres, CEO | S - Sale | $9.17 | -62,000 | 1,387,695 | -4% | -$568,540 | ||||||
2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $0.79 | -3,390 | 440,014 | -1% | -$2,690 | ||||||
2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $0.79 | -3,121 | 215,497 | -1% | -$2,477 | ||||||
2026-05-18 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $0.79 | -1,485 | 118,267 | -1% | -$1,178 | ||||||
2026-05-18 | EXEL | Exelixis, Inc. | Senner Christopher J. | EVP, CFO | S - Sale | $50.00 | -34,901 | 955,040 | -4% | -$1,745,050 | ||||||
2026-05-18 | EXEL | Exelixis, Inc. | Hefti Brenda | SVP, GC | S - Sale | $50.21 | -6,625 | 112,289 | -6% | -$332,641 | ||||||
2026-05-19 | ACOG | Alpha Cognition Inc. | D'Angelo Lauren | COO | P - Purchase | $5.76 | +3,500 | 140,695 | +3% | +$20,160 | ||||||
2026-05-18 | BCRX | Biocryst Pharmaceuticals Inc | McKee Amy E | Dir | S - Sale | $8.97 | -11,180 | 31,252 | -26% | -$100,285 | ||||||
| M | 2026-05-15 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $5.76 | +34,043 | 2,595,993 | +1% | +$196,009 | |||||
2026-05-18 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.92 | +5,700 | 291,566 | +2% | +$5,244 | ||||||
| D | 2026-05-15 | NBIX | Neurocrine Biosciences Inc | Pops Richard F | Dir | S - Sale+OE | $157.65 | -15,000 | 34,480 | -30% | -$2,364,761 | |||||
2026-05-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $132.27 | -3,000 | 173,191 | -2% | -$396,810 | ||||||
| D | 2026-05-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale+OE | $131.29 | -28,000 | 125,779 | -18% | -$3,676,199 | |||||
2026-05-15 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.00 | -1,938 | 412,074 | 0% | -$50,388 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |